
### [MONDO:0021120](http://purl.obolibrary.org/obo/MONDO_0021120)
**Label:** functioning endocrine neoplasm

**Subclasses:** [MONDO:0019933](http://purl.obolibrary.org/obo/MONDO_0019933) (acromegaly), [MONDO:0010492](http://purl.obolibrary.org/obo/MONDO_0010492) (pituitary adenoma, growth hormone-secreting, 2), [MONDO:0017822](http://purl.obolibrary.org/obo/MONDO_0017822) (mixed functioning pituitary adenoma), [MONDO:0019612](http://purl.obolibrary.org/obo/MONDO_0019612) (functioning gonadotropic adenoma), [MONDO:0019611](http://purl.obolibrary.org/obo/MONDO_0019611) (TSH-secreting pituitary adenoma), [MONDO:0003828](http://purl.obolibrary.org/obo/MONDO_0003828) (growth hormone-producing pituitary gland carcinoma), [MONDO:0016035](http://purl.obolibrary.org/obo/MONDO_0016035) (Nelson syndrome), [MONDO:0003837](http://purl.obolibrary.org/obo/MONDO_0003837) (TSH producing pituitary tumor), [MONDO:0003838](http://purl.obolibrary.org/obo/MONDO_0003838) (malignant ACTH producing neoplasm of pituitary gland), [MONDO:0003604](http://purl.obolibrary.org/obo/MONDO_0003604) (functioning pituitary gland neoplasm), [MONDO:0003429](http://purl.obolibrary.org/obo/MONDO_0003429) (functioning pituitary gland adenoma), [MONDO:0003836](http://purl.obolibrary.org/obo/MONDO_0003836) (malignant thyroid stimulating hormone producing neoplasm of pituitary gland), [MONDO:0020479](http://purl.obolibrary.org/obo/MONDO_0020479) (pituitary gigantism), [MONDO:0006238](http://purl.obolibrary.org/obo/MONDO_0006238) (growth hormone-producing pituitary gland adenoma), [MONDO:0017824](http://purl.obolibrary.org/obo/MONDO_0017824) (familial isolated pituitary adenoma), [MONDO:0007052](http://purl.obolibrary.org/obo/MONDO_0007052) (growth hormone secreting pituitary adenoma), [MONDO:0010911](http://purl.obolibrary.org/obo/MONDO_0010911) (prolactin-producing pituitary gland adenoma), [MONDO:0019927](http://purl.obolibrary.org/obo/MONDO_0019927) (growth hormone-producing pituitary gland neoplasm), [MONDO:0017823](http://purl.obolibrary.org/obo/MONDO_0017823) (Somatomammotropinoma), [MONDO:0009050](http://purl.obolibrary.org/obo/MONDO_0009050) (ACTH-secreting pituitary adenoma), 

**Mapped go classes:** [GO:0007191](http://purl.obolibrary.org/obo/GO_0007191) (adenylate cyclase-activating dopamine receptor signaling pathway), [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus), [GO:0005159](http://purl.obolibrary.org/obo/GO_0005159) (insulin-like growth factor receptor binding), [GO:0000166](http://purl.obolibrary.org/obo/GO_0000166) (nucleotide binding), [GO:0005525](http://purl.obolibrary.org/obo/GO_0005525) (GTP binding), [GO:0005887](http://purl.obolibrary.org/obo/GO_0005887) (integral component of plasma membrane), [GO:0004930](http://purl.obolibrary.org/obo/GO_0004930) (G-protein coupled receptor activity), [GO:0007606](http://purl.obolibrary.org/obo/GO_0007606) (sensory perception of chemical stimulus), [GO:0001588](http://purl.obolibrary.org/obo/GO_0001588) (dopamine neurotransmitter receptor activity, coupled via Gs), [GO:0004935](http://purl.obolibrary.org/obo/GO_0004935) (adrenergic receptor activity), [GO:0042383](http://purl.obolibrary.org/obo/GO_0042383) (sarcolemma), [GO:0003924](http://purl.obolibrary.org/obo/GO_0003924) (GTPase activity), [GO:0019001](http://purl.obolibrary.org/obo/GO_0019001) (guanyl nucleotide binding), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0031852](http://purl.obolibrary.org/obo/GO_0031852) (mu-type opioid receptor binding), [GO:0016853](http://purl.obolibrary.org/obo/GO_0016853) (isomerase activity), [GO:0031698](http://purl.obolibrary.org/obo/GO_0031698) (beta-2 adrenergic receptor binding), [GO:0031313](http://purl.obolibrary.org/obo/GO_0031313) (extrinsic component of endosome membrane), [GO:0016579](http://purl.obolibrary.org/obo/GO_0016579) (protein deubiquitination), [GO:0035255](http://purl.obolibrary.org/obo/GO_0035255) (ionotropic glutamate receptor binding), [GO:0007186](http://purl.obolibrary.org/obo/GO_0007186) (G-protein coupled receptor signaling pathway), [GO:0007165](http://purl.obolibrary.org/obo/GO_0007165) (signal transduction), [GO:0007267](http://purl.obolibrary.org/obo/GO_0007267) (cell-cell signaling), [GO:0043235](http://purl.obolibrary.org/obo/GO_0043235) (receptor complex), [GO:0004871](http://purl.obolibrary.org/obo/GO_0004871) (signal transducer activity), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0005622](http://purl.obolibrary.org/obo/GO_0005622) (intracellular), [GO:0006511](http://purl.obolibrary.org/obo/GO_0006511) (ubiquitin-dependent protein catabolic process), [GO:0031748](http://purl.obolibrary.org/obo/GO_0031748) (D1 dopamine receptor binding), [GO:0003755](http://purl.obolibrary.org/obo/GO_0003755) (peptidyl-prolyl cis-trans isomerase activity), [GO:0005834](http://purl.obolibrary.org/obo/GO_0005834) (heterotrimeric G-protein complex), [GO:0051430](http://purl.obolibrary.org/obo/GO_0051430) (corticotropin-releasing hormone receptor 1 binding), [GO:0071880](http://purl.obolibrary.org/obo/GO_0071880) (adenylate cyclase-activating adrenergic receptor signaling pathway), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0031683](http://purl.obolibrary.org/obo/GO_0031683) (G-protein beta/gamma-subunit complex binding), [GO:0036459](http://purl.obolibrary.org/obo/GO_0036459) (thiol-dependent ubiquitinyl hydrolase activity), 

**Class expressions from DL-Learner:**

- [GO:0051430](http://purl.obolibrary.org/obo/GO_0051430) (corticotropin-releasing hormone receptor 1 binding) 53.33%
- [GO:0051429](http://purl.obolibrary.org/obo/GO_0051429) (corticotropin-releasing hormone receptor binding) 53.33%
- [GO:0051428](http://purl.obolibrary.org/obo/GO_0051428) (peptide hormone receptor binding) 53.33%
- [GO:0042383](http://purl.obolibrary.org/obo/GO_0042383) (sarcolemma) 53.33%
- [GO:0035255](http://purl.obolibrary.org/obo/GO_0035255) (ionotropic glutamate receptor binding) 53.33%
- [GO:0031852](http://purl.obolibrary.org/obo/GO_0031852) (mu-type opioid receptor binding) 53.33%
- [GO:0031748](http://purl.obolibrary.org/obo/GO_0031748) (D1 dopamine receptor binding) 53.33%
- [GO:0031698](http://purl.obolibrary.org/obo/GO_0031698) (beta-2 adrenergic receptor binding) 53.33%
- [GO:0031690](http://purl.obolibrary.org/obo/GO_0031690) (adrenergic receptor binding) 53.33%
- [GO:0031683](http://purl.obolibrary.org/obo/GO_0031683) (G-protein beta/gamma-subunit complex binding) 53.33%
- [GO:0031628](http://purl.obolibrary.org/obo/GO_0031628) (opioid receptor binding) 53.33%
- [GO:0005834](http://purl.obolibrary.org/obo/GO_0005834) (heterotrimeric G-protein complex) 53.33%
- [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus) 53.33%
- [GO:0005622](http://purl.obolibrary.org/obo/GO_0005622) (intracellular) 53.33%
- [GO:0005525](http://purl.obolibrary.org/obo/GO_0005525) (GTP binding) 53.33%


